Payment overview · 2025
General Payments
$253,947.28
396 reported records · 11 companies
Healthcare provider profile · identity verified
Douglas L Cunningham, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · PHOENIX, AZ · NPI 1104856475
Verified facts
What the public records show
CMS Open Payments records show Douglas L Cunningham, D.O. received $253,947.28 in general payments during 2025 across 396 reported records.
ViiV Healthcare Company accounted for 64.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Biktarvy, Cabenuva, Descovy, Dovato, Ozempic, Pifeltro, Rukobia, Serostim.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Creon by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Symbicort by this doctor in 2024.
EMD Serono, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Serostim as an associated drug or biological on 153 records involving 74 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Serostim by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Biktarvy as an associated drug or biological on 8065 records involving 2759 distinct recipient NPIs. Public Medicare Part D data also shows 530 claims for Biktarvy by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Descovy as an associated drug or biological on 2032 records involving 589 distinct recipient NPIs. Public Medicare Part D data also shows 131 claims for Descovy by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Vemlidy by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported DELSTRIGO as an associated drug or biological on 864 records involving 608 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Delstrigo by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ISENTRESS as an associated drug or biological on 37 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Isentress by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PIFELTRO as an associated drug or biological on 7921 records involving 2912 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Pifeltro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Ozempic by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Lantus by this doctor in 2024.
ViiV Healthcare Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CABENUVA as an associated drug or biological on 13941 records involving 3305 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Cabenuva by this doctor in 2024.
ViiV Healthcare Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported DOVATO as an associated drug or biological on 18732 records involving 3540 distinct recipient NPIs. Public Medicare Part D data also shows 174 claims for Dovato by this doctor in 2024.
ViiV Healthcare Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RUKOBIA as an associated drug or biological on 3367 records involving 1303 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rukobia by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $164,411.13 | 64.7% | 224 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $66,188.25 | 26.1% | 103 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $9,037.40 | 3.6% | 21 | 2025 |
| Theratechnologies Inc. | Unresolved — no canonical attribution shown | $8,980.99 | 3.5% | 18 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $5,082.40 | 2.0% | 16 | 2025 |
| Napo Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $69.83 | 0.0% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $59.73 | 0.0% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $59.14 | 0.0% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $23.02 | 0.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $21.30 | 0.0% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $14.09 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $179,835.00 | 57 |
| Travel and Lodging | $46,093.44 | 106 |
| Consulting Fee | $11,405.00 | 7 |
| Food and Beverage | $9,377.44 | 222 |
| Honoraria | $7,060.00 | 3 |
| Gift | $176.40 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CABENUVA Normalized: cabenuva |
Drug | ViiV Healthcare Company | $80,565.97 | 104 | 2025 |
Source payment records
|
|||||
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $57,381.36 | 66 | 2025 |
Source payment records
|
|||||
| Biktarvy Normalized: biktarvy |
Drug | Gilead Sciences, Inc. | $24,863.30 | 33 | 2025 |
Source payment records
|
|||||
| RUKOBIA Normalized: rukobia |
Drug | ViiV Healthcare Company | $18,645.10 | 16 | 2025 |
Source payment records
|
|||||
| Descovy Normalized: descovy |
Drug | Gilead Sciences, Inc. | $14,930.72 | 15 | 2025 |
Source payment records
|
|||||
| Yeztugo Normalized: yeztugo |
Drug | Gilead Sciences, Inc. | $10,005.95 | 11 | 2025 |
Source payment records
|
|||||
| EGRIFTA Normalized: egrifta |
Drug | Theratechnologies Inc. | $8,980.99 | 18 | 2025 |
Source payment records
|
|||||
| Serostim Normalized: serostim |
Drug | EMD Serono, Inc. | $7,695.46 | 5 | 2025 |
Source payment records
|
|||||
| PIFELTRO Normalized: pifeltro |
Drug | Merck Sharp & Dohme LLC | $5,052.41 | 15 | 2025 |
Source payment records
|
|||||
| DOVATO Normalized: dovato |
Drug | ViiV Healthcare Company | $189.40 | 6 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $102.94 | 4 | 2025 |
Source payment records
|
|||||
| TROGARZO Normalized: trogarzo |
Drug | Theratechnologies Inc. | $81.73 | 5 | 2025 |
Source payment records
|
|||||
| Mytesi Normalized: mytesi |
Drug | Napo Pharmaceuticals Inc | $69.83 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $59.14 | 4 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $29.99 | 1 | 2025 |
Source payment records
|
|||||
| OCTRODE Normalized: octrode |
Device | Abbott Laboratories | $23.02 | 1 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $21.30 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $18.93 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.93 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $14.09 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Biktarvy biktarvy |
2025 | Biktarvy | 2024 | 530 | exact normalized | Medicare Part D |
| CABENUVA cabenuva |
2025 | Cabenuva | 2024 | 49 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Descovy descovy |
2025 | Descovy | 2024 | 131 | exact normalized | Medicare Part D |
| DOVATO dovato |
2025 | Dovato | 2024 | 174 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PIFELTRO pifeltro |
2025 | Pifeltro | 2024 | 99 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| RUKOBIA rukobia |
2025 | Rukobia | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Serostim serostim |
2025 | Serostim | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| EMD Serono, Inc. Exact reporting entity; no affiliate inference |
2025 | Serostim open payments reported associated product |
CMS Open Payments — General Payments 153 supporting records · 74 recipient NPIs · example record 1236871463 |
Serostim · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Biktarvy open payments reported associated product |
CMS Open Payments — General Payments 8065 supporting records · 2759 recipient NPIs · example record 1234350766 |
Biktarvy · 2024 Exact normalized brand match · 1 Part D row |
530 | 68 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Descovy open payments reported associated product |
CMS Open Payments — General Payments 2032 supporting records · 589 recipient NPIs · example record 1234351196 |
Descovy · 2024 Exact normalized brand match · 1 Part D row |
131 | 18 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | DELSTRIGO open payments reported associated product |
CMS Open Payments — General Payments 864 supporting records · 608 recipient NPIs · example record 1237993240 |
Delstrigo · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | ISENTRESS open payments reported associated product |
CMS Open Payments — General Payments 37 supporting records · 24 recipient NPIs · example record 1238003286 |
Isentress · 2024 Exact normalized brand match · 1 Part D row |
113 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | PIFELTRO open payments reported associated product |
CMS Open Payments — General Payments 7921 supporting records · 2912 recipient NPIs · example record 1237992198 |
Pifeltro · 2024 Exact normalized brand match · 1 Part D row |
99 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ViiV Healthcare Company Exact reporting entity; no affiliate inference |
2025 | CABENUVA open payments reported associated product |
CMS Open Payments — General Payments 13941 supporting records · 3305 recipient NPIs · example record 1189508908 |
Cabenuva · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| ViiV Healthcare Company Exact reporting entity; no affiliate inference |
2025 | DOVATO open payments reported associated product |
CMS Open Payments — General Payments 18732 supporting records · 3540 recipient NPIs · example record 1189508902 |
Dovato · 2024 Exact normalized brand match · 1 Part D row |
174 | 22 |
| ViiV Healthcare Company Exact reporting entity; no affiliate inference |
2025 | RUKOBIA open payments reported associated product |
CMS Open Payments — General Payments 3367 supporting records · 1303 recipient NPIs · example record 1189508926 |
Rukobia · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 530 | 68 |
| Atorvastatin Calcium | Atorvastatin Calcium | 420 | 97 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 339 | 74 |
| Lisinopril | Lisinopril | 276 | 76 |
| Gabapentin | Gabapentin | 242 | 46 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 216 | 44 |
| Levothyroxine Sodium | Levothyroxine Sodium | 205 | 58 |
| Metformin Hcl | Metformin Hcl | 205 | 54 |
| Fluticasone Propionate | Fluticasone Propionate | 182 | 60 |
| Omeprazole | Omeprazole | 179 | 41 |
| Dovato | Dolutegravir Sodium/Lamivudine | 174 | 22 |
| Pantoprazole Sodium | Pantoprazole Sodium | 163 | 38 |
| Amlodipine Besylate | Amlodipine Besylate | 161 | 41 |
| Acyclovir | Acyclovir | 156 | 28 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 154 | 23 |
| Descovy | Emtricitabine/Tenofov Alafenam | 131 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 125 | 23 |
| Tamsulosin Hcl | Tamsulosin Hcl | 123 | 28 |
| Isentress | Raltegravir Potassium | 113 | suppressed |
| Tivicay | Dolutegravir Sodium | 112 | 11 |
| Potassium Chloride | Potassium Chloride | 102 | 15 |
| Bupropion Xl | Bupropion Hcl | 100 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 99 | 22 |
| Pifeltro | Doravirine | 99 | suppressed |
| Symtuza | Darunavir/Cob/Emtri/Tenof Alaf | 98 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 94 | 16 |
| Fluconazole | Fluconazole | 87 | 14 |
| Losartan Potassium | Losartan Potassium | 85 | 29 |
| Zolpidem Tartrate | Zolpidem Tartrate | 85 | 13 |
| Jardiance | Empagliflozin | 84 | 16 |
| Ibuprofen | Ibuprofen | 76 | 17 |
| Prezcobix | Darunavir/Cobicistat | 76 | suppressed |
| Famotidine | Famotidine | 72 | 16 |
| Metoprolol Succinate | Metoprolol Succinate | 64 | 20 |
| Alprazolam | Alprazolam | 62 | suppressed |
| Methylprednisolone | Methylprednisolone | 62 | 43 |
| Montelukast Sodium | Montelukast Sodium | 61 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 60 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 60 | 20 |
| Azithromycin | Azithromycin | 58 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 57 | suppressed |
| Carvedilol | Carvedilol | 56 | 12 |
| Januvia | Sitagliptin Phosphate | 56 | 14 |
| Testosterone | Testosterone | 55 | suppressed |
| Etravirine | Etravirine | 51 | suppressed |
| Cabenuva | Cabotegravir/Rilpivirine | 49 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 48 | suppressed |
| Maraviroc | Maraviroc | 47 | suppressed |
| Eliquis | Apixaban | 46 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 45 | 31 |
| Azelastine Hcl | Azelastine Hcl | 44 | 13 |
| Furosemide | Furosemide | 44 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 43 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 43 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 42 | suppressed |
| Glipizide | Glipizide | 42 | suppressed |
| Nifedipine Er | Nifedipine | 42 | suppressed |
| Triumeq | Abacavir/Dolutegravir/Lamivudi | 41 | suppressed |
| Allopurinol | Allopurinol | 40 | 11 |
| Valacyclovir | Valacyclovir Hcl | 37 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 36 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 35 | suppressed |
| Levetiracetam | Levetiracetam | 35 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 34 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 33 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 33 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 32 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 32 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 32 | suppressed |
| Meloxicam | Meloxicam | 32 | suppressed |
| Ritonavir | Ritonavir | 32 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 30 | suppressed |
| Darunavir | Darunavir | 30 | suppressed |
| Ezetimibe | Ezetimibe | 30 | suppressed |
| Isentress Hd | Raltegravir Potassium | 29 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 27 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 27 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 27 | suppressed |
| Ozempic | Semaglutide | 27 | suppressed |
| Fenofibrate | Fenofibrate | 25 | suppressed |
| Ketoconazole | Ketoconazole | 25 | 15 |
| Odefsey | Emtricitab/Rilpiviri/Tenof Ala | 25 | suppressed |
| Abacavir-Lamivudine | Abacavir Sulfate/Lamivudine | 24 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 24 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 24 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 23 | suppressed |
| Lorazepam | Lorazepam | 22 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 21 | suppressed |
| Delstrigo | Doravirine/Lamivu/Tenofov Diso | 21 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 21 | suppressed |
| Juluca | Dolutegravir/Rilpivirine | 20 | suppressed |
| Lovastatin | Lovastatin | 20 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 20 | suppressed |
| Glimepiride | Glimepiride | 19 | suppressed |
| Serostim | Somatropin | 19 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 19 | suppressed |
| Creon | Lipase/Protease/Amylase | 18 | suppressed |
| Gemfibrozil | Gemfibrozil | 18 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 17 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Pregabalin | Pregabalin | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 16 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | 12 |
| Megestrol Acetate | Megestrol Acetate | 16 | suppressed |
| Tradjenta | Linagliptin | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Loperamide | Loperamide Hcl | 15 | suppressed |
| Simvastatin | Simvastatin | 15 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Efavirenz | Efavirenz | 14 | suppressed |
| Intelence | Etravirine | 14 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Vemlidy | Tenofovir Alafenamide | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | suppressed |
| Clonazepam | Clonazepam | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Humulin R | Insulin Regular, Human | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Rukobia | Fostemsavir Tromethamine | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Complera | Emtricita/Rilpivirine/Tenof Df | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Insulin Syringe | Syrge-Ndl,ins 0.3 Ml Half Mark | 12 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Otezla | Apremilast | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Efavirenz-Emtric-Tenofov Disop | Efavirenz/Emtricit/Tenofovr Df | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Tadalafil | Tadalafil | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $253,947.28 · 396 records | ViiV Healthcare Company | AIRSUPRA, APRETUDE, Biktarvy, CABENUVA, CAPVAXIVE, DOVATO, Descovy, EGRIFTA, GARDASIL 9, MAVYRET, Mytesi, OCTRODE, Ozempic, PIFELTRO, RUKOBIA, Rybelsus, Serostim, TROGARZO, TZIELD, Yeztugo | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Biktarvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error